Peptides

Peptides are chains of amino acids. In topical cosmetics they are conventionally grouped into four functional classes:

• signal peptides, proposed to influence extracellular-matrix signalling;
• carrier peptides, which bind and deliver a cofactor such as copper;
• neurotransmitter-inhibiting peptides, marketed around effects on vesicle signalling;
• enzyme-inhibiting peptides, proposed to reduce the activity of enzymes involved in degradation or pigmentation.

This four-class taxonomy comes from a 2009 narrative review. It is a useful teaching framework, not a regulatory classification and not evidence that all four classes work equally well.^{[18]Topical cosmetic peptides are conventionally sorted into four functional classes — signal (matrikine) peptides, carrier peptides, neurotransmitter-inhibiting peptides and enzyme-inhibiting peptides. This taxonomy comes from a 2009 narrative review by Gorouhi and Maibach; it is a useful teaching framework, not a regulatory or evidential classification, and it does not imply the four classes have comparable evidence behind them.Directly tested by the source[18] Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. 2009 Oct;31(5):327-45.Tier 4}

Common names include palmitoyl pentapeptide-4 (pal-KTTKS, marketed as Matrixyl), acetyl hexapeptide-8 (Argireline) and copper tripeptide-1 (GHK-Cu). Their chemistry, molecular weight, charge and lipidation differ enough that evidence for one does not transfer to another.

Topical peptide serums are cosmetics. In Great Britain they fall under the retained cosmetics framework enforced by OPSS; no peptide-specific pre-market authorisation exists. The labelling and advertising must not imply functions the product does not have. Northern Ireland follows the EU cosmetics regime, so GB compliance should not be presented as a single UK-wide status.^{[17]In Great Britain a peptide serum is a cosmetic product under Regulation (EC) No 1223/2009 as retained and amended by the Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019, enforced by the Office for Product Safety and Standards. Peptides need no pre-market authorisation — a safety dossier goes to OPSS only for new ingredients used as colourants, UV filters or preservatives not already listed in Annexes 4, 5 or 6. What is regulated is the claim: 'the labelling and advertising of cosmetic products must not imply they have characteristics or functions which they do not have.'Directly tested by the source[17] Office for Product Safety and Standards, Department for Business and Trade. Making cosmetic products available to consumers in Great Britain. GOV.UK guidance. Accessed 1 August 2026.Tier 1}

Advertising a peptide as “topical Botox” creates a separate problem. Botulinum toxin is a prescription-only medicine that cannot be advertised to the public. CAP advises marketers not to imply that a cosmetic matches Botox or removes the need for it, and the ASA upheld a “Better than Botox! Injection free” claim when comparative evidence was absent.^{[16]In UK advertising, marketing a peptide product as an alternative or equivalent to Botox is a regulatory risk, not just a scientific one. CAP advice tells marketers to 'avoid implying that their product achieves results comparable to Botox by, for example, depicting syringes or suggesting that their product negates the need for Botox', and the ASA upheld a complaint against 'Better than Botox! Injection free solution for younger skin' because comparative evidence had not been provided.Directly tested by the source[16] Advertising Standards Authority / Committee of Advertising Practice. Advice Online: Beauty and Cosmetics — Botulinum toxin (Botox) products. ASA, London. Accessed 1 August 2026.Tier 1}

Applying an intact-skin cosmetic is different from delivering a material after microneedling, laser or another barrier-disrupting procedure. A human ex-vivo study found 134 ± 12 nanomoles of GHK-Cu crossed microneedle-pretreated skin over nine hours while almost none crossed intact skin. That is evidence of delivery, not of a better clinical outcome. The instructions and intended route for the exact sterile or post-procedure product govern; a retail serum should not be assumed suitable for breached skin.^{[12]GHK-Cu also has a delivery problem despite its small size, because it is highly hydrophilic. In a human ex-vivo skin study, 134 ± 12 nanomoles of peptide crossed microneedle-pretreated skin in nine hours, while 'almost no peptide or copper permeated through intact human skin'. This is a plausible mechanistic argument for pairing copper peptides with microneedling — but it is a delivery finding, not evidence that delivered GHK-Cu improves living skin.Directly tested by the source[12] Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015 Aug;32(8):2678-89.Tier 3}

No peptide-class absolute contraindication was identified in the reviewed evidence. Cautions attach to the finished formulation, its intended route, the condition being addressed and any previous reaction.

A deliberately breached barrier changes the exposure. A product intended only for cosmetic use on intact skin is not made suitable for microneedled or laser-treated skin by the presence of a peptide, and mechanistic delivery evidence does not replace sterility, manufacturer instructions or procedure standards.^[12]

Clients seeking an effect equivalent to injectable botulinum toxin require clear scope separation. A serum cannot be represented as a substitute for a prescription medicine, and an aesthetic practitioner who is not a prescriber does not start or alter toxin treatment.

Active dermatitis, infection, an unexplained wound or a progressive reaction to a product requires the usual pause and assessment rather than continued use on the assumption that peptides are universally inert.

Acetyl hexapeptide-8 for periocular lines

Palmitoyl pentapeptide-4

Copper peptide GHK-Cu

The evidence base as a whole

Selection begins with the named peptide and finished formulation rather than the word “peptide”. A trial of 3 ppm pal-KTTKS, a 10% Argireline emulsion and a copper-peptide cream answer different questions and do not establish a shared effective concentration.^{[5, 6, 7, 9, 10]}

Molecular weight is a useful first check, not a verdict. The widely cited 500 Dalton rule argues that compounds above 500 Da do not cross the stratum corneum. Acetyl hexapeptide-8 is 887–889 Da and palmitoyl pentapeptide-4 is 802 Da, approximately 1.6–1.8 times that proposed limit; uncomplexed GHK is about 340 Da.^{[1, 19, 3]The central obstacle for every topical peptide is size. Bos and Meinardi's widely cited 500 Dalton rule argues that a compound's molecular weight must be under 500 Da to cross the stratum corneum, and that 'larger molecules cannot pass the corneal layer'. Acetyl hexapeptide-8 is 887-889 Da and palmitoyl pentapeptide-4 is 802 Da — roughly 1.6 to 1.8 times the proposed limit. GHK alone is 340 Da and so is the one common cosmetic peptide that sits under it.Directly tested by the source[1] Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x. PMID 10839713.Tier 4[19] National Center for Biotechnology Information. PubChem Compound Summaries: CID 73587 (glycyl-L-histidyl-L-lysine, GHK); CID 9897237 (palmitoyl pentapeptide-4); CID 71587772 (acetyl hexapeptide-3, INCI acetyl hexapeptide-8). US National Library of Medicine. Accessed 1 August 2026.Tier 4[3] Lim SH, Sun Y, Madanagopal TT, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Scientific Reports. 2018;8:1596. doi:10.1038/s41598-017-18454-z. PMID 29371611; PMCID PMC5785486.Tier 3}

The rule was inferred from patterns among allergens, topical medicines and transdermal drugs rather than measured as a hard threshold. It does not account for lipidation, charge, follicles or a barrier altered by a procedure. Product-specific human delivery and clinical data carry more weight than molecular weight alone.^{[1]iThe 500 Dalton rule is a rule of thumb, not a measured law. Bos and Meinardi derived it from patterns among contact allergens, topical drugs and transdermal systems rather than from experiment, and it says nothing about lipidated peptides, charged molecules, follicular delivery, or skin whose barrier has been breached by microneedling, lasers or peels. Practitioners should use it as a prior, not a proof.Inferred from adjacent evidence[1] Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x. PMID 10839713.Tier 4}

For photoageing, prescription tretinoin remains the benchmark. A 2024 systematic review of 25 head-to-head comparisons found insufficient evidence for an alternative first-line therapy and did not identify peptides among its proposed second-line options. In the 1988 vehicle-controlled tretinoin trial, all 30 forearm completers improved on tretinoin but not vehicle, 14 of 15 treated faces improved versus none on vehicle, and histological change was demonstrated in treated forearm skin.^{[13]No peptide has evidence comparable to topical retinoids. A 2024 systematic review of 25 head-to-head comparisons concluded that 'Tretinoin is currently the gold standard therapy for the treatment of photoaging' and that 'there is a lack of substantial evidence to support an alternative first-line therapy'; the only agents it proposed as reasonable second-line options were retinaldehyde, pro-retinal nanoparticles and conjugated AHA-retinoid. Peptides were not among them.Directly tested by the source[13] Siddiqui Z, Zufall A, Nash M, Rao D, Hirani R, Russo M. Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review. American Journal of Clinical Dermatology. 2024 Nov;25(6):873-890.Tier 1[14]The bar peptides have to clear is high. In the definitive 1988 vehicle-controlled trial of topical tretinoin, all 30 completers improved on the tretinoin-treated forearm but not the vehicle forearm, 14 of 15 tretinoin-treated faces improved versus none on vehicle, and — the part peptides have never matched — 'statistically significant histologic changes were seen in forearm skin treated with tretinoin, but not with vehicle cream'.Directly tested by the source[14] Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. JAMA. 1988 Jan 22-29;259(4):527-32.Tier 2}

A 196-woman trial in which a cosmetic regimen performed better than 0.02% tretinoin at eight weeks does not isolate peptides: the regimen also contained 5% niacinamide, antioxidants and 0.3% retinyl propionate, and was funded by P&G Beauty. Every author had a disclosed P&G employment or consultancy relationship.^{[15]The trial most often cited to show a cosmetic peptide product matching a prescription retinoid does not isolate the peptide. In a 196-woman randomised study, a cosmetic regimen improved wrinkle appearance significantly more than 0.02% tretinoin at 8 weeks and comparably at 24 weeks — but that regimen contained 5% niacinamide, antioxidants and 0.3% retinyl propionate alongside the peptides, and the tretinoin comparator was the lowest available strength. It was manufacturer-sponsored. No peptide-specific effect can be extracted.Directly tested by the source[15] Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen. British Journal of Dermatology. 2010 Mar;162(3):647-54.Tier 2}

The instructions for the exact product govern use; the evidence does not establish a generic peptide concentration, layering schedule or post-procedure protocol.

Expected local effects

Use on breached skin

Stopping and referral

Referral is indicated for a suspected infection, persistent dermatitis, an open or non-healing wound, a condition needing diagnosis, or a request for prescription treatment.

Botulinum toxin treatment is a prescription-medicine pathway. A cosmetic peptide may be discussed as a well-tolerated skincare addition, but it cannot be represented as the same treatment or as evidence that injectable toxin is unnecessary.^[16]

Post-laser, post-microneedling or post-peel use sits within the standards and complication pathway for that procedure. Product instructions must explicitly support the route; a mechanistic reason to increase penetration is not an authorisation to apply a retail cosmetic to breached skin.^[12]

Signal peptides are proposed to mimic fragments released during matrix turnover; carrier peptides bind cofactors such as copper; neurotransmitter-inhibiting peptides are proposed to affect vesicle signalling; enzyme-inhibiting peptides are proposed to reduce selected enzyme activity. These are proposed functional categories rather than clinical-effect rankings.^[18]

For acetyl hexapeptide-8, the “Botox-like” account requires delivery to the neuromuscular junction below the dermis. The FDA study detected none in human dermis at 10% after 24 hours, so cosmetic muscle paralysis is not a supported mechanism.^{[2, 3]iThe 'topical Botox' mechanism requires the peptide to reach the neuromuscular junction of the facial mimetic muscles, which sit beneath the dermis. Since no acetyl hexapeptide-8 was detectable in the dermis of human skin even at a 10% concentration in a 24-hour laboratory diffusion-cell study, the botulinum-mimetic mechanism is not supported for cosmetic topical use. Whatever benefit is measured in Argireline trials, it is unlikely to be muscle paralysis.Inferred from adjacent evidence[2] Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutaneous and Ocular Toxicology. 2015 Mar;34(1):46-52. Epub 2014 Apr 22.Tier 3[3] Lim SH, Sun Y, Madanagopal TT, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Scientific Reports. 2018;8:1596. doi:10.1038/s41598-017-18454-z. PMID 29371611; PMCID PMC5785486.Tier 3}

GHK-Cu has extensive cell, gene-expression and animal literature, but almost no peptide crossed intact ex-vivo human skin in the microneedle-delivery study.^{[11, 12]} Biological plausibility does not establish a visible effect from a finished topical cosmetic.

“Argireline is topical Botox.”

“Copper peptides rebuild collagen and reset thousands of genes.”

“Matrixyl has a strong replicated evidence base.”

“The peptide meta-analysis proves topical serums reduce wrinkles.”

• The sample size, control design, randomisation and funding of the 2002 Argireline human observation remain unverified; the origin paper should not carry a precise efficacy promise.^[6]
• Funding for the best-designed Argireline RCT is undisclosed; the effect can be reported, but independence cannot be assumed.^[7]
• No study has linked measured epidermal or dermal peptide concentration with a clinical or histological effect in living human skin; penetration claims therefore do not establish efficacy.
• The 500 Dalton rule may not predict lipidated peptides or procedure-altered skin; product-specific data remain necessary.^{[1, 4, 12]}
• It is unknown whether peptides add benefit to an established routine containing sunscreen and a tolerated retinoid; no additive trial was located, so equivalence or extra benefit should not be promised.
• The microneedling-plus-peptide combination has delivery evidence but no controlled outcome comparison; manufacturer route instructions remain the selection boundary.^[12]
• New multi-peptide complexes have little independent published evidence; absence of evidence does not establish ineffectiveness, but it leaves claims formulation-specific.

Are peptides a substitute for retinoids?

Is Argireline a topical form of Botox?

Do copper peptides have good human evidence?

Can a peptide serum be used after microneedling?

How quickly should a result be expected?

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

1. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x. PMID 10839713.Tier 4Supports: An argumentative/hypothesis paper, NOT a systematic review or an experiment. The authors 'argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer.' Their three arguments are: (1) 'virtually all common contact allergens are under 500 Dalton', (2) 'the most commonly used pharmacological agents applied in topical dermatotherapy are all under 500 Dalton', (3) 'all known topical drugs used in transdermal drug-delivery systems are under 500 Dalton'. Scope limits: this is a rule of thumb derived from drug and allergen precedent, not a measured cut-off for peptides specifically; it says nothing about lipidated or charged molecules, about damaged/microneedled skin, or about follicular routes. It is frequently over-quoted as if it were an experimental finding.Funding / interest: No funding or conflict statement in the PubMed record. Both authors academic (Department of Dermatology, Academic Medical Center, University of Amsterdam).
2. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutaneous and Ocular Toxicology. 2015 Mar;34(1):46-52. Epub 2014 Apr 22.Ex vivoTier 3Supports: US FDA (CFSAN) laboratory study. An oil-in-water emulsion containing 10% acetyl hexapeptide-8 (Ac-EEMQRR-amide, the Argireline molecule) was applied at 2 mg/cm2 to hairless guinea pig (HGP) and HUMAN CADAVER skin in Franz diffusion cells for 24 hours, then washed; skin was tape-stripped and epidermis heat-separated from dermis; quantified by HILIC-MS/MS with stable-isotope-labelled internal standards. Results as percent of applied dose: peptide that penetrated 'remained mostly in the stratum corneum of HGP (0.54%) and human (0.22%)'; 'Total Ac-EEMQRR-amide found in the epidermis of HGP and human skin was similar at 0.01%'; and — the decisive finding — 'No peptide was detected in the dermis or buffer collected underneath the skin for both human and HGP.' No hexapeptide metabolite was detected in any layer. Scope limits: ex vivo excised skin, single 24-hour exposure, one formulation, no living microcirculation, and cadaver skin may under- or over-estimate real barrier behaviour; it measures penetration, not clinical effect.Funding / interest: Conducted by US Food and Drug Administration staff (CFSAN, Office of Applied Research and Safety Assessment). No commercial funding declared. This is one of the few genuinely independent, regulator-run datasets in the topical peptide literature.
3. Lim SH, Sun Y, Madanagopal TT, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Scientific Reports. 2018;8:1596. doi:10.1038/s41598-017-18454-z. PMID 29371611; PMCID PMC5785486.Ex vivoTier 3Supports: Franz-cell permeation of Argireline (Arg0) and three chemically modified analogues through human dermatomed cadaver skin (thigh, 43-year-old Caucasian male, Science Care, Arizona). States Arg0 molecular weight 888.99 Da and LogP -6.37, and that 'With a high molecular weight of 889 Dalton and a low LogP value of -6.3, Arg0 remains mainly on the surface of the skin upon topical application.' Cumulative 24-hour permeation of Arg0 varied non-monotonically with propylene glycol content (e.g. 76.4 ug at 0% PG, 153.2 ug at 30% PG, 53.5 ug at 50% PG, 667.4 ug at 70% PG, 144.4 ug at 100% PG). Modified analogues Arg2 and Arg3 permeated significantly more than Arg0 in most co-solvent systems (e.g. 649.1 ug and 454.1 ug at 100% PG, both p<0.01). In parallel in vitro neuronal work (human dental pulp stem cell-derived neurons), glutamate-release inhibition ranked Arg3 > Arg1 > Arg0 > Arg2 — i.e. the analogue that permeated best was not the one that inhibited best. Scope limits: ex vivo human skin, saturated propylene glycol donor solutions rather than a cosmetic emulsion (so absolute microgram figures are NOT transferable to a retail serum), one donor skin source, no clinical endpoint. Note the 0.22%/0.01% figures quoted in this paper are cited from the FDA study (source 2), not measured here.Funding / interest: Singapore Ministry of Education Academic Research Fund (Tier 1), Singapore National Additive Manufacturing Innovation Cluster (NAMIC), and GRF Biotechnology Inc. (a commercial funder). Authors declare no competing interests.
4. Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules & Therapeutics (Seoul). 2014 Jul;22(4):321-7.Animal studyTier 3Supports: ANIMAL TISSUE STUDY (hairless mouse skin, ex vivo Franz cells; LC-MS/MS quantification). Two findings matter. (1) Enzymatic instability: 'Both KTTKS and pal-KTTKS were rapidly degraded' in skin extracts and homogenates, 'but pal-KTTKS was more stable than KTTKS', and adding protease inhibitors significantly improved stability of both. (2) Permeation: 'neither KTTKS nor pal-KTTKS was detected in the receptor solution, which indicates that neither compound could permeate through the full-thickness hairless mouse skin'. Unmodified KTTKS 'was not detected in any of the skin layers (the stratum corneum, epidermis, and dermis)'. Palmitoylated pal-KTTKS was found at 4.2 +/- 0.7 ug/cm2 in stratum corneum, 2.8 +/- 0.5 ug/cm2 in epidermis and only 0.3 +/- 0.1 ug/cm2 in dermis. Scope limits: MOUSE skin, which is thinner and more permeable than human skin, so human dermal delivery is likely to be lower, not higher; no clinical endpoint; the authors' own conclusion that pal-KTTKS 'may be a useful anti-wrinkle and anti-aging cosmeceutical agent' is an extrapolation not tested here.Funding / interest: No conflict-of-interest statement in the PubMed record; authors are academic (Kyungsung University and Kyungpook National University, South Korea).
5. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005 Jun;27(3):155-60.Tier 2Supports: The single most-cited clinical trial for palmitoyl pentapeptide-4 (pal-KTTKS, sold as Matrixyl). Design: 'Caucasian female subjects (n = 93, aged 35-55) participated in a 12-week, double-blind, placebo-controlled, split-face, left-right randomized clinical study assessing two topical products: moisturizer control product vs. the same moisturizer product containing 3 ppm pal-KTTKS.' Note the concentration: 3 ppm is 0.0003%. Result: 'Pal-KTTKS was well tolerated by the skin and provided significant improvement vs. placebo control for reduction in wrinkles/fine lines by both quantitative technical and expert grader image analysis.' Self-assessed fine line/wrinkle improvement was also significant; other facial parameters showed only 'directional effects' (i.e. not statistically significant). Scope limits: the abstract reports statistical significance but NO effect size, NO confidence intervals and no absolute change figures; Caucasian women 35-55 only; 12 weeks only; split-face against the same moisturiser base, so the comparison is peptide-vs-nothing-added, not peptide-vs-retinoid.Funding / interest: All six authors published from The Procter & Gamble Company, Miami Valley Laboratories, Cincinnati — the sole affiliation in the accessible record. That record does not provide a per-author employment declaration. P&G markets pal-KTTKS-containing products. This is originator/manufacturer research, published in a cosmetic-industry journal.
6. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science. 2002 Oct;24(5):303-10.Tier 3Supports: The origin paper that coined the name 'Argireline' for the hexapeptide Ac-EEMQRR-NH2. Human data reported in the abstract: 'skin topography analysis of an oil/water (O/W) emulsion containing 10% of the hexapeptide on healthy women volunteers reduced wrinkle depth up to 30% upon 30 days treatment.' Mechanistic data: 'Argireline significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin', via interference with SNARE complex formation/stability. No oral toxicity or primary irritation at high doses. Scope limits (important): the PubMed record and abstract give NO sample size, NO control or placebo arm, NO randomisation, NO blinding and NO confidence intervals for the human sub-study; 'up to 30%' is a maximum, not a mean. The mechanistic work is cell-free/in-vitro, so the SNARE inhibition was never demonstrated in intact human skin. The concentration used (10%) is far above what most retail products contain. The paper's conclusion that the peptide 'emulates the action of currently used BoNTs' rests on in-vitro potency, not on human muscle endpoints.Funding / interest: PubMed and Europe PMC list only one affiliation (Centro Biologia Molecular y Celular, Universitas Miguel Hernandez, Alicante) and NO funding or conflict-of-interest statement; the remaining eight authors have no affiliation recorded. The paper names and characterises 'Argireline', which is a registered trade name of Lipotec S.A. (now Lubrizol Life Science). Treat this as originator research, not independent verification. I could not retrieve the full text to confirm individual authors' company affiliations — the publisher page is paywalled.
7. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. American Journal of Clinical Dermatology. 2013 Apr;14(2):147-53.Tier 2Supports: The best-designed published clinical trial of acetyl hexapeptide-8. Design: 'A total of 60 subjects received a randomized treatment of argireline or placebo in a ratio of 3:1' (so roughly 45 active vs 15 placebo), applied to peri-orbital wrinkles twice daily for 4 weeks. Subjective evaluation used Daniell's classification and Seeman's standard; objective evaluation used silicone replicas analysed by a wrinkle-analysis apparatus. Results: 'the total anti-wrinkle efficacy in the argireline group was 48.9%, compared with 0% in the placebo group'; 'the parameters of roughness were all decreased in the argireline group (p < 0.01), while no decrease was obvious in the placebo group (p > 0.05)'. Scope limits: 4 weeks only; 3:1 allocation gives a small placebo arm (n≈15); the headline 48.9% is a SUBJECTIVE global-assessment response rate, not a measured wrinkle-depth change; peri-orbital area only; Chinese subjects only; the abstract gives no concentration for the argireline preparation and no confidence intervals; a 0% placebo response in a cosmetic wrinkle trial is unusually low and warrants caution. Note the same investigators also published an overlapping report in J Cosmet Laser Ther (PMID 23607739) that bundled the human data with a D-galactose-aged MOUSE histology experiment — the collagen findings in that paper are animal, not human.Funding / interest: Not verifiable — the PubMed record carries no funding or conflict-of-interest statement and the Springer full text is paywalled. Given argireline is a proprietary Lipotec/Lubrizol ingredient, independence should not be assumed.
8. Nukaly HY, Halawani IR, Irtaza HM, Alturkistani T, Serafi MR, Alhawsawi W, Bogari HO, Ahmed FA, Alhaddad Y, Shadid A, Alharithy R, Jfri A. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine (Lausanne). 2026 Mar 17;13:1618306.Tier 1Supports: PRISMA systematic review and meta-analysis (PROSPERO CRD420250652779) of MEDLINE, CENTRAL and Web of Science; Cochrane RoB 2; random-effects model. Included 19 RCTs, 1,341 participants, mean age 50.2 +/- 9.1, published 2001-2024. THE CENTRAL FINDING FOR TOPICAL PEPTIDES: only 2 of the 19 trials were topical (105 participants, 7.8%); 17 trials (1,236 participants, 92.17%) were ORAL, overwhelmingly hydrolysed/bioactive collagen peptides. Pooled results: wrinkle reduction MD = 0.27 (95% CI 0.01-0.52, p = 0.04) but 'this benefit was largely driven by oral polypeptides (MD = 1.5, p = 0.01)'; hydration MD = 5.79 (95% CI 3.84-7.75, p<0.01); brightness MD = 2.40 (95% CI 0.76-4.05, p<0.01); elasticity MD = 0.09 (95% CI 0.04-0.24, p = 0.15, NOT significant); density MD = 2.33 (95% CI -1.39-6.05, p = 0.22, NOT significant); roughness MD = -8.47 (95% CI -16.95-0.01, p = 0.05). Heterogeneity was extreme: I2 approximately 100% for wrinkles, 99% elasticity, 98% roughness, 97% density, 92% texture, 88% brightness, 84% hydration. The only topical agents in the included trials were Argireline (acetyl hexapeptide-3) and synthetic alpha-defensin 5 + beta-defensin 3 — Matrixyl/palmitoyl pentapeptide and GHK-Cu appear in the introduction but were NOT represented by any included trial. Authors' own limitation: 'Only two high-quality topical peptide studies met inclusion criteria...findings primarily reflect oral peptide efficacy.' Risk of bias: unclear randomisation in 2 trials, unclear blinding/detection bias in several, high performance bias in one, high attrition bias in two, high 'other bias' in four; all studies low risk for selective reporting.Funding / interest: 'The author(s) declared that financial support was not received for this work and/or its publication.' Authors declare no commercial or financial conflicts. The review does not systematically report industry sponsorship of the included trials.
9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006 Jul-Aug;8(4):252-9.Tier 3Supports: Randomised, blinded-evaluator trial of GHK-Cu skincare after circumoral CO2 laser resurfacing. Thirteen patients completed. Results: 'Computer analysis and blinded evaluators found no statistically significant differences between groups for earlier resolution of erythema. All the patients experienced significant improvement in wrinkles and overall skin quality, but no differences were found between groups.' The ONLY positive was patient-reported: 'The results of the questionnaire indicated a significant difference in the posttreatment improvement of overall skin quality for patients using GHK-Cu (P = .04).' Authors' conclusion: GHK-Cu 'offered no significant reduction or resolution of posttreatment erythema. Objective evaluation found no significant improvement in wrinkles or overall skin quality.' Scope limits: n = 13 is severely underpowered — this is a null result in a small sample, not proof of no effect; post-laser (barrier-disrupted) skin, not intact skin; circumoral area only; the significant patient-satisfaction difference is subjective and unblinded to the patient's own product experience.Funding / interest: No funding or conflict statement in the PubMed record. Investigators are practising facial plastic surgeons (Facial Aesthetic Concepts, San Clemente, California) — no ingredient-manufacturer affiliation apparent.
10. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. 1992 Aug;16(2):251-7.Tier 2Supports: The largest randomised human trial of a topical copper tripeptide preparation I could locate. Prospective, randomised, evaluator-blinded; 86 evaluable patients with venous stasis ulcers; three arms — 1% silver sulfadiazine cream, 0.4% biologically active tripeptide copper complex cream, and inert vehicle placebo. Result: 'Silver sulfadiazine 1% in a cream proved to statistically reduce the ulcer size compared with a biologically active tripeptide copper complex 0.4% cream formulation or the placebo. There was no difference between the latter two treatments.' In other words, GHK-Cu performed no better than vehicle. Scope limits: chronic venous leg ulcers, not facial skin and not cosmetic ageing; 1992 methodology; the endpoint is ulcer area, not collagen or wrinkles. It nonetheless directly tests the wound-healing premise on which the whole GHK-Cu cosmetic story is built.Funding / interest: No funding or conflict statement in the PubMed record. Academic surgical investigators (University of Texas Medical Branch and collaborators).
11. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID 26236730; PMCID PMC4508379.Tier 4Supports: A NARRATIVE review (no search strategy, no inclusion criteria, no risk-of-bias assessment) — it is the source of most of the sweeping claims circulating about copper peptides. Asserts GHK 'stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, as well as supports the function of dermal fibroblasts', with tissue-repair claims 'for skin, lung connective tissue, boney tissue, liver, and stomach lining', plus anti-cancer, anti-inflammatory, anti-anxiety, anti-pain and DNA-repair actions. The companion review (Pickart, Vasquez-Soltero, Margolina, BioMed Research International 2015;2015:648108) states GHK 'is capable of up- and downregulating at least 4,000 human genes, essentially resetting DNA to a healthier state'. Scope limits: the underlying evidence cited is overwhelmingly in-vitro, gene-expression (Connectivity Map analysis) and animal work — rats, mice, pigs, dogs' foot pads — NOT randomised human trials of topical cosmetic use. The cosmetic efficacy statements ('tighten loose skin and improve elasticity, skin density, and firmness, reduce fine lines and wrinkles') are not backed in these reviews by controlled trial citations. Include this source to show WHERE the copper-peptide claims come from, not as evidence that they hold.Funding / interest: All three authors give their affiliation as Skin Biology, Research & Development Department, Bellevue, Washington. The paper states: 'The authors declare that there is no conflict of interests regarding the publication of this paper.' The source package records Skin Biology as a company selling GHK-Cu skincare; the affiliation and no-conflict declaration are therefore disclosed together.
12. Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015 Aug;32(8):2678-89.Ex vivoTier 3Supports: In vitro Franz-cell study of GHK-Cu delivery through human skin with and without polymeric microneedle pre-treatment, plus porcine and cellular safety models. The decisive number: 'In 9 h, 134 +/- 12 nanomoles of peptide and 705 +/- 84 nanomoles of copper permeated though the microneedle treated human skin, while almost no peptide or copper permeated through intact human skin.' The stated rationale is that GHK-Cu skin absorption 'remains challenging due to its hydrophilicity'. Depth and percentage of microneedle penetration correlated with application force, which in turn determined the permeability enhancement. No obvious skin irritation with GHK-Cu after microneedle pre-treatment. Scope limits: ex vivo human skin, 9-hour window, no clinical or histological efficacy endpoint, and it does not establish that delivered GHK-Cu produces any measurable dermal effect in living skin. It is a delivery study, not an efficacy study.Funding / interest: PubMed lists only National University of Singapore (Department of Pharmacy) for the corresponding author; affiliations for co-authors Li B and Leolukman M are not recorded, and no funding or conflict statement appears in the record. Independence not fully verifiable.
13. Siddiqui Z, Zufall A, Nash M, Rao D, Hirani R, Russo M. Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review. American Journal of Clinical Dermatology. 2024 Nov;25(6):873-890.Tier 1Supports: PRISMA systematic review of PubMed and Embase to December 2023; 25 studies comparing topical agents head-to-head with tretinoin; animal studies excluded. Findings: comparators had 'variable efficacy (greater in 7 studies, equivalent in 13 studies, and less in 3 studies)', and 'most studies found the comparator to be less irritating and better tolerated by patients than tretinoin'. The most common comparators were other forms of vitamin A. Authors' verdict: 'Tretinoin is currently the gold standard therapy for the treatment of photoaging'; 'given that most studies comparing topical therapies with tretinoin are of poor quality and/or demonstrate bias, there is a lack of substantial evidence to support an alternative first-line therapy.' The only agents they name as reasonable second-line options are 'retinaldehyde, pro-retinal nanoparticles, and conjugated alpha-hydroxy acid and retinoid (AHA-ret)' — PEPTIDES ARE NOT AMONG THE AGENTS PROPOSED AS AN ALTERNATIVE. Scope limits: photoaging only; head-to-head comparisons only, so single-arm or vehicle-controlled peptide work is outside its scope; quality of included studies is explicitly described as poor.Funding / interest: No commercial funding indicated in the record; authors are academic/hospital dermatology (New York Medical College, Metropolitan Hospital, New York).
14. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. JAMA. 1988 Jan 22-29;259(4):527-32.Tier 2Supports: The benchmark against which any peptide claim should be measured. 16-week randomised, double-blind, vehicle-controlled study; all patients applied tretinoin to one forearm and vehicle to the other, and half received tretinoin to the face. Results: 'All 30 patients who completed the study showed statistically significant improvement in photoaging on the tretinoin-treated forearms, but not on the vehicle-treated forearms. Fourteen of the 15 patients who received tretinoin to the face had improvement in photoaging, whereas none of the vehicle-treated patients' faces improved, a statistically significant difference.' Crucially: 'Statistically significant histologic changes were seen in forearm skin treated with tretinoin, but not with vehicle cream' — histological, not just cosmetic, change. Side effects limited to irritation of tretinoin-exposed skin. Scope limits: n = 30 completers, 16 weeks, 1988 methodology, prescription-strength tretinoin (not cosmetic retinol). Cited here as the comparator standard: histological confirmation is what the peptide literature lacks.Funding / interest: No funding statement in the PubMed record; academic dermatology (University of Michigan). Note that tretinoin research of this era was substantially supported by Ortho Pharmaceutical, though this is not recorded in the abstract.
15. Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen. British Journal of Dermatology. 2010 Mar;162(3):647-54.Tier 2Supports: The closest thing in the literature to a peptide-versus-retinoid head-to-head — and it does not isolate peptides. 8-week randomised parallel-group study in 196 women with moderate to moderately severe periorbital wrinkles after a 2-week washout; cosmetic arm n = 99, tretinoin arm n = 97; subject cohorts (n = 25) continued for a further 16 weeks. The cosmetic regimen was an SPF 30 lotion containing 5% niacinamide, peptides and antioxidants, plus a niacinamide/peptide cream, plus a targeted product containing niacinamide, peptides AND 0.3% retinyl propionate — i.e. a multi-ingredient regimen containing a retinoid ester. Results: 'The cosmetic regimen significantly improved wrinkle appearance after 8 weeks relative to tretinoin, with comparable benefits after 24 weeks. The cosmetic regimen was significantly better tolerated than tretinoin through 8 weeks by all measures.' Scope limits, and they are decisive: because the active regimen bundled 5% niacinamide, antioxidants and 0.3% retinyl propionate with the peptides, NO peptide-specific effect can be extracted from this trial. The tretinoin comparator was the lowest available strength (0.02%). 8-week primary window; only 50 subjects total continued to 24 weeks.Funding / interest: The paper states that Fu, Bertucci, Grimes, Mandy, Perez and Weinkle were paid consultants to Procter & Gamble; Hillebrand, Raleigh, Li, Marmor and Kaczvinsky were P&G employees. Every author therefore had a P&G financial relationship. The study was funded by Procter & Gamble Beauty, which markets the cosmetic regimen tested.
16. Advertising Standards Authority / Committee of Advertising Practice. Advice Online: Beauty and Cosmetics — Botulinum toxin (Botox) products. ASA, London. Accessed 1 August 2026.Tier 1Supports: UK advertising law position directly relevant to 'topical Botox' peptide marketing. States: 'Botox is a prescription-only medicine (POM) and as such, cannot be advertised to the public (rule 12.12)'. On cosmetic products claiming Botox-like results: 'Marketers should take care to avoid implying that their product achieves results comparable to Botox by, for example, depicting syringes or suggesting that their product negates the need for Botox.' Cites an upheld ruling against 'Better than Botox! Injection free solution for younger skin' because 'evidence showing that the product could achieve the same or better results than undergoing Botox treatments had not been provided' (Rejuvenex Direct UK Ltd, 10 October 2012, rule 12.2). Also flags that before/after photographs constitute an efficacy claim, and that indirect promotion via terms such as 'cosmetic injections' breaches the rules (Valterous Ltd, 18 December 2024). Scope: applies to UK marketing communications under the CAP/BCAP Codes; it is not a scientific assessment of peptides.Funding / interest: Independent UK advertising regulator; no commercial funding.
17. Office for Product Safety and Standards, Department for Business and Trade. Making cosmetic products available to consumers in Great Britain. GOV.UK guidance. Accessed 1 August 2026.Tier 1Supports: Confirms the framework that governs peptide-containing skincare in Great Britain: the applicable law is 'Regulation (EC) No 1223/2009 on Cosmetic Products, as amended by the Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019', enforced by the Office for Product Safety and Standards. It applies to products 'sold or given away (for example, free samples) and products used on the public by professionals'. On claims: 'The labelling and advertising of cosmetic products must not imply they have characteristics or functions which they do not have.' A safety dossier must be submitted to OPSS only for new colourants, UV filters and preservatives not listed in the annexes. Scope limits: this specific guidance page does not name peptides, does not cite Regulation (EU) No 655/2013 (the common criteria for claim justification) and says nothing about medicinal claims — so it establishes the framework, not a peptide-specific ruling. Separate GOV.UK material confirms the Responsible Person must ensure claim wording complies with the common criteria in Regulation (EU) No 655/2013 as it has effect in GB law.Funding / interest: UK Government (Department for Business and Trade); no commercial funding.
18. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. 2009 Oct;31(5):327-45.Tier 4Supports: The reference that established the taxonomy now used industry-wide. States that 'Peptides and proteins, frequently used for this purpose, were categorized into four groups: signal peptides, enzyme-inhibitor peptides, neurotransmitter-inhibitor peptides and carrier peptides,' and reviews 'controlled ex vivo or in vivo efficacy studies on any topical peptide or protein that has been administered to treat signs and symptoms of ageing.' Scope limits: this is a NARRATIVE review (described as 'comprehensive' but with no PRISMA search strategy, no risk-of-bias appraisal and no meta-analysis in the abstract); it is a classification and appraisal paper, not evidence of efficacy for any peptide; and it is now 17 years old. I could not access the full text (publisher paywall returned HTTP 402), so effect sizes and per-peptide verdicts inside the paper are not verified here.Funding / interest: No funding or conflict statement in the PubMed record; academic dermatology (University of California, San Francisco). Howard Maibach has held extensive consultancy relationships across the cosmetic and chemical industries over his career, which is not disclosed in this record.
19. National Center for Biotechnology Information. PubChem Compound Summaries: CID 73587 (glycyl-L-histidyl-L-lysine, GHK); CID 9897237 (palmitoyl pentapeptide-4); CID 71587772 (acetyl hexapeptide-3, INCI acetyl hexapeptide-8). US National Library of Medicine. Accessed 1 August 2026.Tier 4Supports: NIH chemical database records giving verified molecular weights: GHK (the tripeptide, before copper complexation) C14H24N6O4, MW 340.38 g/mol; palmitoyl pentapeptide-4 (pal-KTTKS, Matrixyl) C39H75N7O10, MW 802.1 g/mol; acetyl hexapeptide-8 C35H62N14O11S, MW 887.0 g/mol (reported as 888.99 Da in the peer-reviewed permeation literature, source 3). Scope limits: this is a chemistry database, not evidence of any biological or clinical effect. Molecular weight alone does not determine skin penetration — charge, logP, lipidation and formulation all matter — but these figures are what the 500 Dalton rule is applied to.Funding / interest: US National Institutes of Health; no commercial funding.